Patented Medicine Prices Review Board seeks applicants for Chairperson position
| Patented Medicine Prices Review Board Canada | news releases
Patented Medicine Prices Review Board seeks applicants for Chairperson position
News results
Showing 31 - 40 of 79 results
Increased use of higher-cost medicines continues to put pressure on Canadian public drug plans
| Patented Medicine Prices Review Board Canada | news releases
High-cost drugs accounted for over one third of total drug costs in 2019-20 but were only used by 2% of beneficiaries.
Coverage of oncology medicines well aligned across Canadian provinces, but sources of funding differ
| Patented Medicine Prices Review Board Canada | news releases
The Patented Medicine Prices Review Board published the second in a three part report series on Alignment Among Public Formularies in Canada
High cost patented drugs now account for 50% of sales
| Patented Medicine Prices Review Board Canada | news releases
Federal Minister of Health tables the 2019 Annual Report of the Patented Medicine Prices Review Board
New drugs entering Canada at steady rate over past 5 years
| Patented Medicine Prices Review Board Canada | news releases
Canada still among top 10 OECD countries in terms of access to new drugs
Oncology treatments continue to dominate the drug development pipeline
| Patented Medicine Prices Review Board Canada | news releases
The latest edition of the Patented Medicine Prices Review Board (PMPRB) Meds Pipeline Monitor reports that oncology continued to dominate the therapeutic mix of the drug pipeline in 2020.
High-cost drugs drive increased public drug plan spending in Canada
| Patented Medicine Prices Review Board Canada | news releases
Annual expenditures on drugs in public plans exceeded $12 billion in 2018-19
Sales of cancer medicines in Canada nearly tripled over the past decade
| Patented Medicine Prices Review Board Canada | news releases
Today, the PMPRB, under the National Prescription Drug Utilization Information System (NPDUIS) initiative, released a chartbook on the market for oncology medicines in Canada.
Canada’s drug price watchdog ready to apply new powers to protect Canadians from surging high cost drugs
| Patented Medicine Prices Review Board Canada | news releases
PMPRB completes five year consultative process to strengthen and modernize its regime with release of new Guidelines
PMPRB releases updated draft Guidelines for public consultation
| Patented Medicine Prices Review Board Canada | news releases
The PMPRB is holding public consultations on its proposed new pricing Guidelines